Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

(2014) N. A. O'Brien et al.   CLINICAL CANCER RESEARCH

Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells

(2014) Manabu Kaneko et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

(2014) Fabrice André et al.   LANCET ONCOLOGY

The mTOR Inhibitor Rapamycin Synergizes with a Fatty Acid Synthase Inhibitor to Induce Cytotoxicity in ER/HER2-Positive Breast Cancer Cells

(2014) Chen Yan et al.   PLoS One

Overcoming Treatment Resistance in HER2-Positive Breast Cancer

(2012) Fabio Puglisi et al.   DRUGS

The mTOR Signalling Pathway in Human Cancer

(2012) Helena Pópulo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

New Synthetic Inhibitors of Fatty Acid Synthase with Anticancer Activity

(2012) Carlos Turrado et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors

(2011) Shikha Gaur et al.   CANCER LETTERS

Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer

(2010) G. Oliveras et al.   Annals of the New York Academy of Sciences

High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer

(2010) Jiyoung Rhee et al.   BREAST CANCER RESEARCH AND TREATMENT

Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition

(2010) G. Zoppoli et al.   CURRENT CANCER DRUG TARGETS

Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells

(2009) Thomas W. Grunt et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance

(2009) Rajiv Dua et al.   BREAST CANCER RESEARCH AND TREATMENT

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity

(2009) T. Puig et al.   CLINICAL CANCER RESEARCH

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

(2009) E. A. Mittendorf et al.   CLINICAL CANCER RESEARCH

Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer

(2009) Toshiro Migita et al.   JNCI-Journal of the National Cancer Institute

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

(2009) Francisco J. Esteva et al.   Nature Reviews Clinical Oncology

p63 Promotes Cell Survival through Fatty Acid Synthase

(2009) Venkata Sabbisetti et al.   PLoS One

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight

(2007) Susan Aja et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY